

INDEX

- Abe (Kyoto legal scholar), 165
Abe, Shinzo, 157, 159, 250
abortion, 102
Academia Japan, 168–169
Academia, Business and Clinical approach, 227
Academies of Military Medical Sciences (AMMS), 73, 76
Accelerated Approval Program, 114
acceleration. *See* regulatory acceleration
acceptable science, 27, 44, 52, 82, 147
access to treatment, 114–115, 238
acquisitive desire, 26, 213
 caring solidarity and, 269–271
 social contract and, 243
acquisitive imitation, 264
Act for the Promotion of Regenerative Medicine (Japan), 158
Act on the Safety of Regenerative Medicine (RM Act) (2013), 58, 158, 166, 169
 fatalities and, 234
 GMP and, 173
 international brokerage and, 225
 regulatory immunity and, 240
 JSRM and, 222
 Taiwan and, 236
active brokerage, 210–212, 216, 219, 221, 238–239
 forms of, 217
Adams, Rachel, 270
 imitative desire and, 264
adaptive licensing, 236
ADIPOA1, 119
Administrative Measures for Clinical Research for Stem Cells (Trial Implementation) (CFDA 2015), 68, 237–238, 282
Advanced Medical Treatment status (Japan), 159
Advanced Regenerative Medicine and Biopharmaceutical Safety and Support Act (2019), 233
Advanced Therapy Medicinal Products (ATMP), 50, 118–120
adverse trial effects, 106, 117, 179
advertising, 117
affordability, 104, 121
 alternative regulation and, 252
 political desire and, 105
 R-CPX and, 136–137
agency, 23
 lateral political pressures and, 215
 regulatory capitalism and, 64
 regulatory discrepancy and, 208
Agency for Medical Research Development (AMED), 158, 165, 178, 238
 global brokerage and, 229–230
 industrial investment and, 252
age-related macular degeneration (AMD), 163, 166, 170, 178
 state investment and, 250
Agreement on Trade Related Investment Measures (TRIMS), 11
AIFA (Italian Medicine Agency), 120
Ali, Robin, 251
All Japan System (AJS), 30, 155–156, 159–162, 169–171, 174–177
 approval-mechanisms and, 178–180
 collaboration and, 163–165
 funding and, 178–180

- All Japan System (AJS) (cont.)
 - funding overhaul and, 159
 - iPSC research and, 165–169
 - misrecognition and, 177–178
 - politics and, 163
 - scientific constraints and, 163–174
 - vision of, 178
- alleviation of suffering, 266
- Alliance for Harmonization of Cellular Therapy Accreditation (AHCTA), 60
- Alliance for Regenerative Medicine (ARM), 230, 232
 - formulation of regulations and, 45
 - Japan and, 151
- allogeneic stem cell therapy, 11
 - AJS and, 170–171
 - Australia and, 116
 - Category-3 drugs and, 70
 - CiRA and, 170
 - immune suppressants and, 176
 - Stempeutics and, 81–83, 85
 - transfusion and, 173
- alternative medicine, 2, 63
 - Beike and, 111
 - health activism and, 204
- alternative regulation
 - affordability and, 252–253
 - credible authority and, 97
 - Guangzhou Alliance and, 75
 - regulatory brokerage and, 64
 - regulatory immunity and, 106
- Alzheimer's Disease, 234
- Amcell, 72
- American Association of Blood Banks (AABB), 61, 109, 111
- An Yihua, 73
- Anspach, Mark, 96, 259–260
- anything goes attitude, 65
- Arendt, Hannah, 9
- Asia
 - AJS and, 160, 164–165
 - fraudulent providers and, 41
 - global brokerage and, 230
 - HOs and, 186, 195
 - individual-rights discourses and, 202–203
 - IOMD and, 183
 - Japanese–Thai collaboration and, 132
 - patient populations and, 261
 - regulatory harmonisation and, 144
 - regulatory overhaul and, 42
 - stem cell tourism and, 182
 - unreliability and, 37
- Asia Partnership Conference of Regenerative Medicine Associations, 230
- Asian Cellular Therapy Organization (ACTO), 236
- Asian financial crisis of 1987, 36
- Asian Stem Cells, 57
- Asian Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs, 230
- assays (iPSCs), 167–169, 175–176
- Association of Southeast Asian Nations (ASEAN), 134, 141
 - regulatory capital and, 145
 - Thai Revised Drug Act and, 144
- Astro Stem, 234
- Athersys, 59
- AusBiotech Regenerative Medicine Advisory Group (RMAG), 117
- Australia, 116–118
 - caring solidarity and, 241
 - EU and, 120
 - regulatory reputation and, 121
- Auto-Culture®, 129, 143
- autologous stem cell therapy, 11–12
 - Australia and, 116–117
 - caring solidarity and, 241
 - Crohn's and, 255
 - HICs and, 112
 - Parkinson's Disease and, 170
 - pay-to-participate and, 115
 - regulatory immunisation and, 122
 - same surgical procedure exception and, 114
 - Takahashi pilot study and, 170
- automation, 128–130, 143, 227. *See also* Japanese–Thai collaboration
- AveXis, 249
- Ayurveda, 192

- Bayh-Dole Act (US), 159
 BaYi Brain Hospital, 73
 Beijing University, 109
 Beike Biotechnology Company, 29,
 56–57, 108–112
 ICMS and, 61
 patient ethics and, 111–112
 stem cell tourism and, 102
 universal regulation and, 122
 Bell, Catherine, 25
 regulatory redemption and, 153
 Bharadwaj, Aditya, 103
 Bianco, Paolo, 104
 bilateral organisation, 217, 228
 biliary cirrhosis, 70
 bioethics, 16–18, 23
 acceptable science and, 44, 94
 Beike patients and, 111–112
 caring solidarity and, 271
 hegemony and, 69
 local considerations and, 151
 markets and, 96
 practice of, 76
 rational individualism and, 263
 recklessness and, 102
 regulatory immune-tolerance and, 95
 scientific integrity and, 101
 scientific uncertainty and, 99
 socio-political positions and, 152
 toeing the regulatory line and, 76
 unethical binary with, 123
 universal application of, 106
 universal appraisals of, 105, 107
 ‘Bioethics Briefing Note’ (UK Nuffield
 Council), 17
 biologics, 114
 Australia and, 116–117
 regulatory immunisation and, 121
 South Korea and, 233
 Biologics License Applications (BLAs), 51
 biology, 43
 conceptual uses of, 92
 biomedical platform theory, 66
 biomedical platforms, 78–79, 81–83
 disjointedness of, 85
 LMICs and, 88
 Stempeutics and, 83, 87
 technological rationale of, 89
 biomedical products
 clinical research and, 40
 human rights-based discourse and, 204
 BioNexus-status companies, 56
 Biostar Research Institute, 234
 Biosystems, 167
 biotechnology, 185, 266–268
 well regulated forms of, 113
 Black, Julia, 4, 7, 215
 bona fide science practices, 42, 63
 bone marrow-derived mesenchymal
 stem cells (BM-MSC), 70
 FDA and, 104
 GvHD and, 74
 thalassemia and, 136
 boundary-making. *See* regulatory
 boundary-making
 boundary-work. *See* regulatory
 boundary-work
 bowel- and bladder-management, 187,
 194
 Braithwaite, John, 5, 35
 Brazil, 42
 Breakthrough Therapy Designation, 51,
 114
 Brexit, 238
 Brian Salter, 258
 bribery, 111
 brokerage. *See* regulatory brokerage
 Bufacchi, Vittorio, 8
 bureaucracy, 9, 97
 free individuals and, 205
 Japan and, 156
 Japanese–Thai collaboration and, 130
 rogue science and, 111
 Busch, Lawrence, 34
 Bush, George W., 41, 152

 California Institute for Regenerative
 Medicine (CIRM), 232
 Calvert, M. J., 213
 Cambodia, 131
 Cambrosio, Alberto, 82
 Canada, 81
 capacity building. *See* regulatory
 capacity building
 capital. *See* regulatory capital
 capitalism. *See* regulatory capitalism

- Caplan, Arnold, 104
 caring solidarity, 19, 23, 26–27, 269–271
 competition and, 246
 competitive desire and, 31, 241
 regulatory brokerage and, 212, 214
 regulatory concepts and, 212
 Cartistem, 58, 233
 case studies, 18–19
 Castells, Manuel, 35
 catching-up policies, 66
 category-3 drugs, 68, 70
 caution, 267
 Celgene, 249
 Celixir, 238
 cell and gene therapies (CGTs), 227
 Cell and Gene Therapy Catapult, 226
 cell banks, 249
 biobank initiatives and, 60
 HLA and, 12
 standards for, 175
 See also umbilical cord blood banks (UCB)
 cell ossification, 130
 cell processing, 173
 smart form of, 229
 Cell Products & National Engineering Research Center, 71–72
 cell reprogramming, 11–12, 156–157, 172
 cell sourcing, 11, 171
 politics of, 178
 Cell Surgical Network (CSN), 115
 cell therapy products (CTPs), 174–175
 advertised as cell treatment, 53
 Taiwan and, 236
 CellSeed, 222
 cell-sheet therapy, 221–222
 Heartsheet and, 225
 Cellular Biomedicine Group Inc. (CBMG), 62
 Central Drugs Standard Control Organisation (CDSCO), 80
 Central Military Commission (China), 72
 central planning, 34
 Centre for Biosystems Dynamics Research, 177
 Centre for Cells and Tissue Engineering, 74
 Centre for iPS Cell Research and Application (CiRA), 163–167, 169–170, 174–175, 178–179
 AJS led by, 169, 171–172, 177
 branding for, 168
 changes to protocols and, 168
 criticisms of, 176
 Kyoto University and, 133
 pilot study by, 172–173
 pressure to work with, 173
 Takahashi and, 171
 Yamanaka and, 157, 160–162
 charities, 188
 HOs and, 203
 Doctor Chaturvedi (pseudonym), 83
 Chen, Y.-C., 236
 China, 55, 111–112
 2009 regulations and, 108–109, 112
 2015 draft regulation and, 73, 75
 2015 regulation and, 77
 AJS and, 164
 Beike Biotech and, 29, 108–112
 CAMS and, 70–71
 elite laboratories and, 88
 entry into global science-competition and, 42
 forms of authority in, 48
 Guangzhou Alliance and, 74–75
 Guangzhou use of local authority in, 49
 hegemonic approaches and, 66, 69
 HOs and, 205
 industry collaboration and, 197–198
 international networks and, 60–62
 Japan and, 237–238
 Japanese–Thai collaboration and, 138
 knowledge activism and, 202–203
 LMIC collaboration and, 57
 lobbying in, 190
 military research and, 72–73
 MSC safety and, 104
 needs of disabled and, 190–191
 NGOs and, 188
 off-label use in, 49
 regulatory boundary-work and, 64
 regulatory brokerage and, 215

- regulatory capacity building and, 67–69
- regulatory immunity and, 92, 240
- regulatory orientation and, 69–71, 75–78
- regulatory reputation and, 102
- SCI and, 194–195, 200
- semi-private enterprises and, 75–76
- shared scientific cultures and, 52
- stem cell trials in, 13
- Tianjin stem cell cluster and, 71–72
- UK and, 101
- universal regulation and, 107, 122
- US unauthorised clinics and, 115
- China Bone Marrow bank, 72
- China Disabled Persons Federation (CDPF), 189
- China Food and Drug Administration (CFDA), 68
 - Administrative Measures of Clinical Research for Stem Cells (for Trial Implementation) (CFDA 2015), 68, 237–238, 282
 - Beike and, 109
 - BM-MSCs and, 70
 - Guangzhou Alliance and, 75
- China SCI-Net, 61
- China-bashing, 111
- Chinese Academy of Medical Sciences (CAMS), 70–71
 - collaboration with, 76
 - military research and, 73
 - Peking Union Medical College and, 71
- Chinese Academy of Sciences (CAS), 73
- Chinese Medicine Registry and Management System, 69
- chongsaem law ('cutting-edge regenerative' law), 233
- Choose Wisely, 266
- chronic and life-limiting illnesses, 254
- Chulalongkorn University (CU), 29, 124–125, 139, 219–221
- Cipla, 82–83
- CITIC (China International Trust and Investment Corporation), 75
- Class 1 treatments, 224
- clinical firsts, 250
- clinical research, 121
 - biomedical products and, 40
 - Japan and, 159
 - national vs. local permission for, 49
 - vindication of, 152
- Clinical Research Organisations (CROs), 261
- clinical research trials (CRTs), 2
 - AJS and, 154–155, 173
 - biotech industry and, 88
 - clinical, 14
 - clinical research and, 166
 - cost-benefit analysis of, 254–256
 - high expectations of participation in, 255
 - Indian bureaucracy and, 52
 - onus of risk and, 22
 - pathways for, 169–171
 - patient populations and, 260–263
 - PMDA and, 158
 - RCTs and, 53–55
 - regulatory challenges and, 16–18
 - regulatory threshold for, 157
 - research therapy tension and, 15
 - safety and efficacy studies of, 165
 - social contract and, 257–258
 - state investment and, 252
 - stem cell therapies and, 12
 - tension between therapy and, 14–15
 - See also* randomised control trials (RCTs)
- ClinicalTrials.gov, 12, 109, 115
- Coca-Cola, 197
- collaboration, 1, 3, 18, 124–126
 - AJS and, 163–165, 168, 177–179
 - alternative therapeutic practices and, 63
 - anything goes attitude and, 65
 - case studies of, 19
 - China and, 76
 - CiRA and, 174
 - company competition and, 172
 - competition and, 29, 64, 123
 - competitive desire and, 213
 - Guangzhou Alliance and, 74–75
 - health organisations and, 189, 196–198
 - increase in regulatory competition and, 42

- collaboration (cont.)
 - industry and, 175
 - Japanese universities and, 159
 - Japan–Thailand and, 131–133, 140–145
 - local authority and, 49
 - loose regulation and, 56
 - networks for, 44
 - niches for, 124
 - R-CPX and, 127–128
 - regenerative therapy and, 176–177
 - regulatory brokerage and, 64, 209
 - regulatory capital and, 145–147
 - regulatory discrepancies and, 130–131
 - regulatory immunity and, 239
 - regulatory knowledge and, 22
 - regulatory manipulation and, 35
 - regulatory orientation and, 77–78
 - regulatory patterns in, 244
 - regulatory redemption and, 150–151
 - scientific results of, 133–135
 - trust and, 137–139
- commodification, 263
- common good, 265–266
- communal norms, 96
- community, 187–188, 204, 263–265
 - common good and, 265
 - SCI and, 182
- commutative justice, 268
- compassionate treatment, 50, 223
- competition, 2, 17
 - Australia and, 117
 - biological notions of, 213
 - clinical firsts and, 210
 - collaboration and, 29, 64, 123, 146
 - company affiliation as cause of, 172
 - destructive forms of, 216
 - international dynamics of, 62
 - Japan and, 233–234
 - mimetic rivalry and, 93–94
 - regulatory brokerage and, 209
 - regulatory capacity-building and, 88
 - regulatory capital and, 125
 - regulatory capture and, 40
 - regulatory reform and, 231
 - regulatory violence and, 3
 - structural spaces for, 100
 - UK and, 101
 - unreliability and, 37
- See also* competitive desire; regulatory capitalism; regulatory violence
- competitive desire, 23–24, 26–27, 30
 - caring solidarity and, 31, 241, 269–271
 - collaboration and, 124–126
 - common good and, 265
 - Cossu and, 253
 - cost-benefit analysis and, 248
 - costs of, 253
 - foreseeable harm and, 238, 243
 - Girard and, 93
 - governance and, 250–251
 - Japan's 2013 reforms and, 30
 - legal justice and, 269
 - mimesis and, 263–264
 - mimetic rivalry and, 97
 - regulatory brokerage and, 209, 211–214
 - regulatory reform and, 240
 - scapegoating and, 29
 - scientific value and, 252
 - social contract and, 246, 256, 258
 - state investment and, 45
 - virtue ethics and, 269
- compliance, 5, 44, 55
- Comprehensive Special Zones, 225–226
- conditional approval, 230
 - AJS and, 180
 - India and, 235
 - REGROW Bill and, 241
 - Stempeucel and, 235
 - Taiwan and, 236
 - time-conditions and, 224, 229–230, 236
 - US and, 254
- conflict avoidance, 146
- conflict, collaborative contexts for, 126
- contract development and
 - manufacturing companies (CDMOs), 249
- contract research organisations (CROs), 73
- Control and Supervision of Drugs and Products from Stems Cells amendment (Thailand), 131

- corneal cells, 218
- cosmetic therapy, 53, 80, 84–85, 89
 Japanese–Thai collaboration and, 131
 reputational effects of, 21
- Cossu, Giulio, 243, 253–254, 256–258
- cost-benefits analysis, 254–256
 community action and, 267
 competitive desire and, 248–249
 regulatory violence and, 248
 virtue ethics and, 269
- cost-effectiveness of treatment, 254
- COVID-19, 214
- creative desire, 27, 32
 caring solidarity and, 212, 263–265, 270
 generative principle of, 246
 mimesis and, 212
 regulatory concepts and, 211
- creative mimesis, 263–264
- Critical Limb Ischemia, 87
- critical theory, 181
- Crohn's disease, 58, 254–255
- Croley, Steven, 6
- cryopreservation, 84
- Cupistem, 58, 233
- Custom Market Insight (CMI 2023), 249
- Cyranoski, D., 179
- cytokine production capacity, 84
- Cytori Therapeutics, 59, 84
- Dallas Buyer's Club* (film), 181
- Dana and Christopher Reeves Act, 200
- Deane-Drummond, Celia, 266–268, 270
- Deinsberger, Julia, 12
- Deloitte, 238
- democratic decision-making, 94, 258
- Demouchel, Paul, 126, 259
- Department of Biotechnology (DBT) (India), 80, 86, 218
 ISSCR criticism and, 235
- Department of New Energy and Industrial Technology Development Organization (NEDO), 125, 132, 137, 219–220
 regulatory capital and, 145
 regulatory tolerance and, 147
- deregulation, 4, 30, 113
 as form of brokerage, 217
 FTCM and, 183, 231
 international brokerage and, 226
 international health organisations and, 241
 international patient movements and, 154
 Japan and, 224–225, 229
 neoliberalism and, 36
 regulatory capital and, 146
- desire, 243
 forms of, 269–271
- destructive desire, 243
- developmental pathways, 81–83
 length of, 227
 regulatory orientation and, 78–79
 therapy provision and, 80
- dialectic of co-production, 150–151, 155, 163
- dialectic of regulatory reproduction, 151
- Diet (parliament of Japan), 222
- difference. *See* regulatory difference
- diplomatic immunity, 92
- direct-to-consumer provision (DTCs), 107, 122
 Australia and, 117
 caring solidarity and, 241
 Japanese–Thai collaboration and, 130
- disability, 190–193
 China classifications of, 189
 self-perception of, 187
 societal roots of, 184
- discrepancy. *See* regulatory discrepancies
- disease conditions, 254
- distributive justice, 268
- diversity, 206
- donation vs. leasing, 132, 136, 138–139, 145
- down-regulation, 162, 181, 184, 186, 223
 misrecognition and, 153
 patient movements and, 30
 regulatory redemption and, 30, 154, 205

- Drug Administration Law (China, 2001), 67
- Drug Controller General (India), 80
- Drugs and Cosmetics Act (1940), 235
- Drugs and Cosmetics Act (DCA), 80
- Drugs Controller General, 87
- dual-track systems, 236–237
- Duchenne muscular dystrophy (DMD), 50, 193
 - cost-effectiveness and, 254
 - personal decision-making and, 255
- Dupuy, Jean-Paul, 271
- Early Access to Medicine Scheme, 51
- early-access programs, 238
- ‘The East or Scientific Feast’ (Anonymous, *Economist* Magazine), 41
- Eastern Europe, 183
- economic growth, 13, 26, 59, 64, 246
 - Australia and, 117
 - competitive desire and, 250
 - LMICs and, 121
 - regulatory brokerage and, 209
 - regulatory violence and, 248
 - targets for, 66, 88
- economic metaphors, 92
- elites, 25, 43–44, 67, 93
 - CAMS proactive orientation and, 71
 - funding and, 69
 - importing regulation by, 81
 - Japanese–Thai collaboration and, 147
 - network criticism by, 72
 - regulation and, 40
 - regulatory boundary-work and, 88
- embodied conditions, 31
- embodied ideals, 153
- embodied identities, 103, 184, 203–204
- embryo sourcing, 11
- empathy, 27
- enablement, 113, 123
- endogenous stem cell therapy, 11
- Entrepreneurial life-science networks, 44
- entrepreneurial networking, 82
- entrepreneurialism, 117, 183, 207, 210–212
 - innovation and, 52
 - prohibitive regulation and, 239
 - regulatory brokerage and, 216
 - regulatory gaps and, 206
 - science management and, 31
 - Tianjin cluster of, 71
 - unauthorised therapies and, 115
- Esposito, Robert, 95
- ethics, 16–18
 - acceptable science and, 44, 94
 - Beike patients and, 111–112
 - caring solidarity and, 271
 - ethics, 23
 - hegemony and, 69
 - local considerations and, 151
 - markets and, 96
 - practice of, 76
 - rational individualism and, 263
 - recklessness and, 102
 - regulatory immune-tolerance and, 95
 - scientific integrity and, 101
 - scientific uncertainty and, 99
 - socio-political positions and, 152
 - toeing the regulatory line and, 76
 - unethical binary with, 123
 - universal application of, 106
 - universal appraisals of, 105, 107
- ethics of return, 56
- ethnocentrism, 204
- Europe, 227–228
 - Beike image in, 109
 - blood donation in, 173
 - compassionate treatment and, 223
 - FDA and, 151
 - international patient movements and, 154
 - knowledge activism and, 202
 - lay-expert input and, 197
 - modernity and, 113
 - patient movements and, 183
 - patient populations and, 261
 - private interest theories in, 6
 - registries in, 201
 - soft law and, 48
 - trust in state regulators in, 205
 - UK and, 251
 - unauthorised clinics in, 22
 - US and, 232

- European Bank for iPSCs (EBiSC), 60
- European human Pluripotent Stem Cell Register (hPSCreg), 60
- European Medicines Agency (EMA), 48, 51, 100, 118–120
- Biologics and, 116
- direct-to-consumer and, 122
- Orphan Drug Designation and, 51
- regulatory capital and, 145
- regulatory immunisation and, 121
- WHO and, 123
- European Union (EU), 118–120
- 2007 Regulation and, 100
- accelerated approval and, 51
- compassionate treatment and, 50
- Hospital Exemption clause in, 116
- influence of reform and, 231
- Japanese reform and, 232
- Japan–Thailand collaboration and, 128
- market acceleration and, 51–52
- patient protection in, 100
- piecemeal regulation and, 59
- RCTs and, 53–55
- regulatory boundary-work and, 64
- regulatory dynamics of, 63
- regulatory exemptions and, 22
- regulatory overhaul and, 42
- regulatory tolerance and, 121
- standards set by, 67
- European Union Tissue and Cells Directive, 118
- Eurostemcell (2022), 60
- evidence-based medicine, 15
- exemptions, 116
- acceleration and, 205
- Australia and, 117
- HICs and, 121
- US and, 115
- expanded access, 114–115
- related mechanisms for, 223
- experimental practices, 16–18, 63
- Australia and, 116–117
- Beike and, 111
- collaborative scientific results and, 133
- HOs and, 205
- political desire and, 105
- protection of human subjects in, 14
- regulatory exemptions for, 50–51
- regulatory immunity and, 94
- Wharton's jelly cells as, 120
- experimentation. *See also* innovation
- exploitation, 93, 95
- exploited regulatory brokerage, 26
- family banking, 72
- family care, 192
- RCTs as alternative to, 106
- FBRI (Foundation for Biomedical Research and Innovation), 164, 167, 176
- FDA Safety Innovations Act (FDASIA), 51
- French-Constant, Charles, 120
- fieldwork, 19–20
- Five-year Healthcare Innovation Strategy, 222
- Five-year Medical Innovation Programme, 160
- flexibility. *See* regulatory flexibility
- Foong, Patrick, 117
- Fordist production management, 35
- foreignness, 24
- clinical trials and, 205
- experimental medicine and, 106
- regulation and, 25, 28
- scapegoating and, 96
- See also* rogue practices
- foreseeable harm, 1–3
- caring solidarity and, 269
- competitive desire and, 243
- definitions of violence and, 8–9
- mimetic cultures and, 244
- politics and, 29
- regulatory brokerage and, 209–212, 215, 238
- regulatory violence and, 247
- table of concepts including, 211
- See also* regulatory violence; violence
- foresight, 267
- Forum for Innovative Regenerative Medicine (FIRM), 175, 221–222
- companies within, 226
- global brokerage and, 229–230
- US influence and, 232

- Foundation for Biomedical Research and Innovation (FBRI), 166
- four-phased trials, 14, 16, 53–55
- France, 251
 - soft law and, 48
- fraudulent science, 42
- Free to Choose Medicine (FTCM), 181, 206, 231–232
 - deregulation and, 154
 - EU and, 120
 - HOs and, 183–184
 - lobbying and, 190
- freedom of choice, 200
- fresh-cell therapy, 118
- Friedman, Milton, 34, 36
- Fukuoka Trinity Clinic, 234
- funding, 156–159
 - AJS and, 175, 177
 - Bush moratorium on, 152
 - CiRA and, 174
 - developmental pathway length and, 227
 - elite laboratories and, 69
 - HOs and, 189
 - hybrid forms of, 71
 - Japan and, 223
 - redirection of, 256
 - virtue ethics and, 269
- G-10 group, 36
- GATT rules, 144
- GEN website, 249
- General Agreement on Trade in Services (GATS), 36
- genetic testing, 187
- genome analysis, 166
- Germany, 118
- Gieryn, Thomas, 37, 42
- gift economies, 259–260
- gift-giving, 263–264
- Girard, Rene, 26, 31, 93, 213
 - imitative desire and, 264
 - mimetic rivalry and, 100
- global hegemony approach, 66
- Global North, 184
- Global Regenerative Medicine Market Report – 2019 (GRMMR), 249
- Global South, 184
- globalisation, 29, 100
 - caring solidarity and, 270
 - collaboration and, 124
 - competition and, 28
 - hegemonic approaches to, 65–66
 - illegitimate regulatory brokerage and, 244
 - nation-states and, 246–248
 - neoliberalism and, 33–36
 - patient populations and, 261
 - pioneering industries and, 89
 - regulatory brokerage and, 228–231
 - regulatory discrepancies and, 242
 - regulatory gaps and, 239
 - social contract and, 259–260
 - variability and, 44
 - See also* international regulation
- Dr Gong, 110
- Good Clinical Practice (GCP), 55, 237
- Good Gene, Cell and Tissue Practice (GCTP), 169, 171
- Good Laboratory Practice (GLP), 36, 49
 - India and, 235
 - Japan–Thailand collaboration and, 127–128
 - PMD pathway and, 169
 - scarcity of resources and, 39
 - Thailand and, 141–142
- Good Manufacturing Practice (GMP), 36, 49, 55, 107
 - collaborative science and, 133
 - India and, 235
 - industrial standards and, 176
 - non-homologous use and, 113
 - PMD pathway and, 169
 - R-CPX and, 130, 135
 - RM Act and, 173
 - scarcity of resources and, 39
 - state investment and, 251
 - Thailand and, 141–142
 - good practice requirements, 55
 - governance, 208
 - AJS and, 159–163
 - competitive desire in, 250–251
 - HOs and, 186–190
 - knowledge activism and, 199–201, 203
 - See also* politics

- Graft versus Host Disease (GvHD), 50,
70, 74–75
controversial applications of, 105
R-CPX and, 137
Temcell and, 225
grass-root organisations, 188. *See also*
patient organisations
grey experimental industries, 117
GTP (good tissue practice), 55
Guangzhou Alliance, 74–75
Guangzhou City Large S&T Expert
Program, 74
Guangzhou Huanhuang, 75
Guangzhou Hygiene Department, 75
Guangzhou Institute for Biomedicine
and Health (GIBH), 74
Guangzhou Province, 49, 61
Guangzhou Stem Cell and Regenerative
Medicine Alliance, 61
Guidance for Research and Evaluation
of Cellular Therapy Products
(China), 237
Guidelines for Stem Cell Research and
Therapy (India), 80–81
- Haelios, 171
Han, Zhongchao, 71–72
Hanshi, 75
Hanshi (Beijing Health and Biotech
Group), 72
Haraway, Donna, 92
hard law, 48, 52, 58
harmonisation. *See* regulatory
harmonisation
Hashigawa (from FBRI), 176, 223
Hayek, Friedrich, 34
Headquarters of Healthcare Policy
(Japan), 158
Healios, 166, 177
Health and Pharmaceutical Promotion
Strategy, 155, 160, 164
health organisations (HOs), 185–186
cost-effectiveness and, 254
deregulation and, 241
diverse needs of disabled and,
190–193
down-regulation and, 254
health activism and, 203–204
industry and, 196–198, 253
internationalisation of, 181–184
knowledge activism, 199–203
locally situated demands and,
193–196
patient wishes and, 184
personal decision-making and, 255
political governance and, 186–190
political identity and, 204–206
See also networks; organisational
levels; patient organisations
Healthcare Engineering Group, 129
healthcare insurance, 159, 224, 253
Beike and, 111
biotechnology ethics and, 267
cost-benefit analysis and, 255
globalisation and, 260
industry seeking payouts from, 197
national schemes for, 106
universal coverage and, 136–137
Hearticellgram, 58, 233
Heartland Institute, 183, 231
Heartsheet, 225
hegemony, 63
approaches to, 65–66
down-regulation and, 184
ethical conformity and, 69
health activism counter to, 204
LMICs and, 88
patient movements and, 182
regulatory capacity building and, 89
regulatory redemption and, 150
hematopoietic stem cells (HSCs), 10–11
Thailand and, 140
Zhao research on, 70
heterogeneous cell lines, 12
high-income countries (HICs), 3,
121–122
biotechnological solutions and, 185
biotechnology ethics and, 267
bureacracy and, 205
caring solidarity and, 264
collaboration and, 124
Cossu and, 253
cost and, 254
counter-hegemony and, 204
enablement and, 123
experimental practices and, 63

- high-income countries (HICs) (cont.)
 hegemony theories and, 66
 HOs and, 186, 189
 industry collaboration and, 196–198
 knowledge activism and, 199–203
 MD and, 195
 MSCs and, 99
 needs of disabled and, 191
 political lobbying in, 190
 regulatory brokerage and, 209
 regulatory gaps and, 206
 regulatory tolerance and, 112
 SCI and, 193, 195
 sustainability of healthcare in, 21
 view of fraudulent science in, 42
 ‘Highway to the Realization of
 Regenerative Medicine’ (Japan),
 157
 HLA (human leukocyte antigen)
 matching, 11–12
 holistic medicine, 53
 home-keeping strategy (Japan), 230
 homologous use, 113
 Hong Kong University of Science and
 Technology, 109
 horizontal pressure, 215
 Hoshino, Toshihiko, 160, 162
 Hospital Exemption (HE) (EU), 50,
 116, 119–120, 223
 Article 5(1), 50
 non-routine use and, 53
 House of Lords (UK), 238
 debate in, 251–252
 Huaxia Ganxibao Lianmeng (Beijing
 Health and Biotech Group), 72
 human embryonic stem cell research
 (hESC), 175–176
 Bush 2001 moratorium on, 41
 hESC moratorium and, 41
 investment in, 13
 IPS cells and, 156
 Japan and, 157
 upscaling production of, 249
 US funding cuts and, 101
 human-rights discourse, 184
 Hunan Guangxiu Biological Science
 Co., Ltd., 76
 Hunan Guangxiu Hospital, 76
 Hunan Provincial government, 76
 Hwang Woo-Suk, 41, 194, 196, 198
 Hybrid Assistive Limb (HAL®), 194
 ideal regulation, 78
 inequality and, 146
 identity, 184
 care and, 268
 discursive messaging and, 96
 normalcy and, 256
 imitation, 26, 100
 caring solidarity and, 270
 Girard and, 213
 imitative desire, 93, 97
 objectification of others and, 264
 immature therapies, 16
 immune reactions, 12
 immune suppressants, 176
 immune tolerance. *See* regulatory
 immune tolerance
 immunitarian force, 93–94
 immunitary politics, 125
 regulatory capital and, 148
 immunitas, 93–97
 immunological rejection, 170
in vitro generation, 13
 India, 52, 55
 2007 stem cell guidelines and, 86
 2013 regulation and, 235
 bureaucracy in, 52
 elite laboratories and, 88
 globally shared patient needs and,
 204
 Guidelines for Stem Cell Research
 and Therapy in, 80–81
 hegemonic approaches and, 66
 HO recognition in, 190
 HO registries and, 201
 HOs and, 205
 human rights discourse and, 203
 industry collaboration and, 197
 international guidelines and, 67
 Japan and, 234–236
 Japanese–Thai collaboration and,
 138
 kosher/rogue binary in, 103
 LMIC collaboration and, 56
 needs of disabled and, 190–192

- NGOs and, 188
- off-label use in, 49
- phase three trials and, 181
- regulatory boundary-work and, 64
- regulatory immunity and, 92, 240
- responsible innovation in, 78–79
- SCI and, 194, 200
- stem cell tourism and, 195
- Stempeutics and, 83–84
- Stempeutics model and, 85–87
- UK and, 101
- ZCRM and, 218–219
- Indian Council of Medical Research (ICMR), 52, 80–81, 86, 218
- Indian Institute of Science (IISc), 82
- indirect violence, 7–8
- individual responsibility, 248
- individual-rights discourses, 202–203
 - health activism and, 204
- induced pluripotent stem cells (iPSCs), 10–12
 - AJS and, 155, 160–162, 174–179
 - AMD and, 163
 - assays for, 167–169
 - CiRA and, 163–166, 171–173
 - clinical trial pathways for, 169–171
 - collaborative science and, 133
 - competitive desire and, 250
 - creation of, 156–157
 - discovery of, 41
 - GMP conditions and, 173
 - investment in, 13
 - Japanese regulation of, 58
 - politics of, 156
 - publication and, 134
 - regenerative therapy and, 165
 - research success and, 158–159
 - state investment and, 249–250
 - Yamanaka Nobel Prize and, 136
- industry, 171
 - AJS and, 175–176
 - Australia and, 117
 - HO collaborations with, 189
 - HOs and, 196–198, 253
 - individual-rights discourses and, 203
 - investment and, 88
 - Japanese investment and, 223–224
 - Japanese–Thai collaboration and, 142
 - regulatory gaps and, 206
 - responsible image of, 86
 - state investment and, 252–253
- inequality, 146–147
 - political movements and, 154
- infections, 176
- infrastructure, 261, 269
 - effective creation of, 77
- Japan and, 158
- Initiatives under the Project for Japan
 - Translational and Clinical Research Core Centers policies (Japan), 158
- innovation, 4
 - contested science and, 105
 - exemptions for, 50
 - market acceleration and, 51–52
 - regulatory orientation and, 88
 - responsibility and, 78–79, 81, 86
 - See also* experimentation
- Institute for Biomedical Research and Innovation (IBRI), 167
- Institute of Hematology (PUMC), 71–72
- Institutional Committee for Stem Cell Research (IC-SCR), 80, 235
- Institutional Ethics Committee (IEC) (India), 80
 - guidelines from, 219
- institutional review boards (IRBs), 16, 49
 - Guangzhou Alliance and, 75
 - Thailand and, 140–141
- Integrated Cell-Material Sciences (iCeMS), 164
- intellectual property rights (IPR), 43–44
 - Beike and, 110
- intentionality, 8
- interest groups, 215
- interest-group theory, 6
- 'Interim Regulations on the Ethical Review of Biomedical Research Involving Human Subjects' (MoH 2007), 67
- internal mirroring, 92–93
- International Alliance for Biological Standardization (IABS), 176

- International Association of Neurorestoratology (IANR), 61, 97
- International Cellular Medicine Society (ICMS), 60
 - credible authority and, 97
- International Clinical Trials Registry Platform (ICTRP), 12
- International Consortium of Stem Cell Networks (ICSCN), 60
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), 229
- International Monetary Fund (IMF), 36
- International Organization for Muscular Dystrophy (IOMD), 182
- International Organization for Spinal Cord Injury (IOSCI), 182
- International Pharmaceutical Regulatory Harmonization Strategy, 230
- international regulation, 5, 24
 - 2008–2014 period for, 62
 - China's adaptation of, 112
 - Chinese state laboratories and, 111
 - collaboration and, 124
 - competition and, 2, 34
 - credible authorities for, 97
 - global competition and, 27
 - global dynamics of, 18–19
 - guidelines and, 55
 - health organisation standards and, 205
 - hegemony and, 88
 - HOs and, 181–184
 - international, 47
 - knowledge of, 22
 - participation in, 45
 - patient movements and, 30
 - regulatory boundary-work and, 60–62
 - regulatory brokerage and, 239
 - regulatory capital and, 145–146
 - unauthorised clinics and, 108
 - See also* globalisation
- International Society for Cellular Therapy (ISCT), 60, 67
 - formulation of regulations and, 45
 - Japanese–Thai collaboration and, 134
 - social contract and, 260
- International Society for Stem Cell Research (ISSCR), 60, 62, 67, 229
 - China and, 237
 - credible authority and, 80
 - formulation of regulations and, 45
 - India criticised by, 235
 - Japan and, 151
 - Japanese–Thai collaboration and, 134
 - regulatory capital and, 145
 - scarcity of resources and, 39
 - social contract and, 260
- International Society of Plastic Surgeons, 85
- International Stem Cell Bank Initiative (ISCBI), 60, 167
 - defining pluripotency and, 174
 - industrial standards and, 176
- International Stem Cell Forum (ISCF), 60
- International Stem Cell Initiative (ISCI), 43, 60
- International Stem Cell Registry (ISCR), 60
 - inverse care law, 256
- investigational new drugs (INDs), 49, 115
 - CiRA and, 173
 - Japan and, 223
 - US and, 115
- investigational use, 80
 - FTCM and, 183
- investment, 88, 171
 - caring solidarity and, 269–270
 - Japanese industry and, 223–224
 - political desirability and, 104
 - state support for, 249–250
 - virtue ethics and, 269
- in-vitro fertilisation (IVF), 75–76
- Invitrogen (ABI), 167
- Invossa, 233
- ischemic stroke trials, 73
- Italy, 119, 197
 - AIFA medical agency and, 120
 - regulatory tolerance and, 121
- Japan, 124–127
 - Australia and, 117
 - caring solidarity and, 241

- China and, 237
 competitive desire and, 250
 competitive reform and, 233–234
 conditional approval and, 231
 fast-track pathways and, 57–60
 forms of brokerage and, 217
 FTCM and, 231
 funding overhaul in, 156–159
 global brokerage and, 229–231
 HOs and, 194–195, 205
 India and, 234–236
 industry collaboration and, 198
 informal brokerage and, 219
 informal regulatory brokerage and, 218
 international brokerage and, 224–228
 knowledge activism and, 202
 LMIC collaboration and, 56
 market acceleration and, 51
 national insurance and, 253
 other country experiences similar to, 253
 patient financial contributions in, 106
 reform and, 30, 127
 regulatory boundary-work and, 64
 regulatory brokerage and, 239
 regulatory capacity building and, 217
 regulatory dynamics of, 63
 regulatory immunity and, 240
 regulatory overhaul and, 42
 SCI and, 201
 shared scientific cultures and, 53
 social contract and, 258
 soft law and, 48
 South Korea and, 232
 state investment and, 250, 252
 state support brokerage and, 219–221
 stem cell trials in, 13
 Taiwan and, 236–237
 tax on legacies in, 188
 UK and, 238, 252
See also All Japan System (AJS)
 Japan Medical Association, 165
 Japan Muscular Dystrophy Association (JMDA), 195
 Japan Revitalization Strategy, 219
 Japan Science and Technology Agency (JST), 163–165
 Japanese Society of Regenerative Medicine (JSRM), 221–222, 234
 Japanese–Thai collaboration, 124–127, 131–133, 143–145
 R-CPX and, 133–135
 regulatory capital and, 145–147
 regulatory discrepancies and, 130–131
 state support brokerage and, 219–221
 Jerne, Niels, 92
 Jiao Hong, 215
 Jordana, Jacint, 5, 35
 judgement, 267. *See also* community judicial systems, 94
 June, 249
 justice, 27, 32, 214, 265–266, 268–269
 caring solidarity and, 212, 270
 common good and, 265–266
 creative desire and, 263
 local notions of wisdom and, 246
 patient protection and, 15
 sacrificable victims and, 259
 See also caring solidarity
 Kanagawa Centre for Clinical Research and Strategy, 226
 Kanishka (pseudonym), 82
 Kawa (researcher at iCeMS), 163–164
 Kawasaki (Japan), 226
 Kawasaki Heavy Industry (KHI), 29, 124–129, 143–144
 collaborative scientific results and, 133–135
 Japanese–Thai collaboration and, 131–132
 medical use and, 136–137
 regulation and, 140–143
 regulatory capital and, 145, 147
 state support brokerage and, 219–221
 trust and, 138–139
 Keating, Peter, 82
 Keihin Coastal Areas Comprehensive Special Zone for International Competitiveness, 225–226

- Keio University, 160
 KenCare, 57
 Keynesianism, 34
 Kishi (scientist), 172–173
 knowledge activism, 190, 196, 199–203
 knowledge assets, 14, 132, 134, 178
 Kolon TissueGene, 233
 Korean Food and Drug Administration (KFDA), 57, 232–233
 Korean Ministry of Food and Drug Safety (MFDS), 58
 kosher practices, 29, 103
 discursive identification and, 97
 foreign practices and, 24
 grey areas and, 95
 regulatory immunity and, 93
 K-Stemcell, 57
 Kuala Lumpur (Malaysia), 87
 Kumar, M. (pseudonym), 82–85, 218
 kusakariba ‘cutting from the hay-meadow commons’, 225
 Kyoto University, 160
 Centre for iPS Cell Research and Application (CiRA), 133
 off the shelf cells and, 171
 Kyoto University Hospital (KUH), 170
 RM Act and, 173
 Kyoto University Medical School, 164

 Lancet Report (Cossu et al.), 243
 Lanphier, Edward, 230
 ‘Large-scale cell production of stem cells for clinical application using the automated cell-processing machine’ (Kami et al. 2013), 133
 last resort treatment, 75
 Latin America, 182
 Latour, Bruno, 113
 law, 95
 establishment of, 93–94
 rule of, 15, 36
 transcendental power and, 96
 legal justice, 268
 Levi-Faur, David, 5
 regulatory state approach and, 5
 liberalism, 34
 Life Innovation Centre (LIC), 226
 Life Technology, 167

 Lifecell, 61
 Lippmann, Walter, 34
 lobbying, 35, 188, 190
 active brokerage and, 239
 FTCM and, 190
 health funding priorities and, 45
 localities, 44, 63
 caring solidarity and, 270
 collaboration and, 49
 creative desire and, 264
 dilemmas of, 66
 disability and, 190–193
 Guangzhou Alliance and, 75
 hegemony and, 89
 ideal regulation and, 78, 105–107
 international networks and, 60–62
 international regulation and, 67
 jurisdictional differences and, 23
 knowledge activism and, 201
 LMICs and, 56, 122
 local practices, 31
 locally situated demands and, 193–196
 organisational networks and, 216
 patient populations and, 261–262
 prudence and, 265
 regulation in, 20, 63
 regulatory boundary-work and, 46
 regulatory brokerage and, 243
 regulatory capacity building and, 77–78, 211
 regulatory contagion and, 147
 regulatory orientation and, 69, 77
 regulatory redemption and, 149–154
 rogue experimentation and, 103
 self-help solutions and, 267
 shared scientific culture and, 52
 therapy provision and, 27
 wisdom and, 246, 263, 268
 workspaces and, 188
 loopholes, 116
 loose regulation, 56
 loving desire, 263
 lower and middle-income countries (LMICs), 1
 Beike Biotech case and, 108, 111
 biotechnology ethics and, 266–267
 collaboration and, 124
 Cossu and, 253

- economic growth in, 121
- hegemony and, 65–66, 89
- HOs and, 186, 193–194, 204–206
- industry collaboration and, 198
- international guidelines and, 67
- investment by, 14
- knowledge activism and, 199–200, 202–203
- local communities and, 263–265
- MSCs and, 99
- needs of disabled and, 192
- neoliberalism and, 64
- network complexity and, 70
- patient financial contributions and, 106
- patient movements and, 182
- regulatory boundary-work and, 59, 88–89
- regulatory dynamics of, 63
- regulatory immunity and, 105
- regulatory redemption and, 25
- SCI and, 195
- scientific ambitiousness and, 55
- shared scientific cultures and, 52
- small country investment and, 56–57
- sustainability of healthcare in, 21
- universal regulation and, 122
- Western hegemony and, 41
- Lu Daopei hospitals, 77
- Lu Guangxiu, 75–76
- Magellan Stem Cells, 116
- Majone, Giandomenico, 5–6
- major histocompatibility complex (MHC)–matched iPSCs, 170
- Malaysia, 56–57, 64
 - Stempeutics branch in, 81–82, 85, 87
- Malaysian Biotech Corporation, 56
- malpractice, 80
- Management Measures for the Clinical Use of Medical Technologies (MoH), 68
- Management of Clinical Research and Transformation Applications for Somatic Cell Therapy (China), 237
- ‘Manifesto for Slow Science’ (Stengers), 214
- Manipal Education and Medical Group (MEMG), 81–83
- Manipal Hospital, 82
- Manohar, B. N., 235
- Professor Manote, 140–141
- manufacturing, 250
 - facility construction in, 249
- markets, 26, 31, 259–260
 - absence of regulation for, 131
 - automation and, 144
 - Depuy on, 271
 - distancing mechanism of, 248
 - ethics and, 96
 - innovative acceleration and, 51–52
 - Japanese–Thai collaboration and, 132, 144
 - national permission for, 49
 - neoliberalism and, 33–36
 - PMDA and, 158
 - product functionality and, 85
 - R-CPX and, 139
 - responsive-market tools and, 5
 - scientific applications and, 159
 - social contract and, 258
 - Stempeutics and, 87
 - time-limited authorisation and, 224
- Martin, Emily, 92
- Marxism, 34
- Masayo, Takahashi, 165
- Master, Z., 122
- Medical Council of Thailand (MCT), 130, 140–142
- medical device regulation, 62
- Medical Practitioners Act (Japan), 223, 232
- Medical Research Council (MRC) (UK), 238
- medicinal signaling cells, 104
- Medicines Adaptive Pathways to Patients (MAPPs), 51, 119
- Medicines and Healthcare products Regulatory Agency (MHRA) (UK), 227
 - Early Access to Medicine Scheme and, 51
- Melton, Doug, 215, 237
- Memorandum of Understanding (MOU), 197–198

- mesenchymal stem cells (MSCs),
 - 10–11, 104–105
 - national income and, 99
 - patient funding and, 117
 - safety and, 104–105
 - Tianjin stem cell cluster and, 72
 - upscaling and, 130
- mesenchymal stromal cells, 104
- Mesoblast, 59
- Metchnikoff, Elie, 92
- methodology, 21–23
- Michael J. Fox Foundation for
 - Parkinson's Research (MJFF), 254
- military research, 70, 72–73
 - immunity metaphors and, 92
- mimetic desire, 243
 - Others and, 211
- mimetic principle, 31
- mimetic rivalry
 - caring solidarity and, 270
 - competition and, 100
 - competitive desire and, 97
 - discursive messaging and, 96
 - regulatory immune-tolerance and, 95
 - regulatory immunity and, 93–98
 - scapegoating cultures and, 103
- mimetic theory, 212–213
 - creative desire and, 265
 - creative mimesis and, 263–264
- minimal manipulation, 53, 117–118, 235
- Ministry of Economy, Trade and
 - Industry (METI) (Japan), 157, 233
- Ministry of Education (China), 74
- Ministry of Education, Culture, Sports,
 - Science and Technology (MEXT)
 - (Japan), 157, 160, 164
- Ministry of Health (MoH) (China), 67–68
 - hESR guidelines and, 102
 - January 2012 Notification by, 73
 - PLA and, 72
 - Tianjin UCB and, 71
- Ministry of Health, Welfare and Labor
 - (MoHWL) (Japan), 58, 142, 157–158, 195
 - competition and, 234
 - global brokerage and, 230
 - Parkinson's Disease and, 170
 - PMD pathway and, 169
 - Takahashi and, 163
 - whole-genome sequencing costs and, 170
- Ministry of Science and Technology (MoST), 70
- minor histocompatibility antigen (MHA), 170
- Mirowski, P., 159
- misrecognition, 31
 - AJS and, 155, 163, 165, 177–178
 - international brokerage and, 228
 - life-saving medicine and, 211
 - politics of, 156
- misrepresentation, 264
 - misrecognition and, 228
- modernity, 112–113
- monopoly, 3, 9, 34
- morally binding action, 267–268
- multi-centre clinical trials, 55
- Multi-Stem, 50
- muscular dystrophy (MD), 30, 185–188
 - diverse needs of disabled and, 190–192
 - embodied identities and, 204
 - industry collaboration and, 197–198
 - knowledge activism and, 200–202
 - locally situated demands and, 193, 195–196
 - patient movements and, 183
 - political governance and, 186–188, 190
- muscular skeletal disorders, 175
- mutations, 170
- mutual surveillance, 118
- mutuality, 26, 74
 - CRT participation and, 258
 - Depuy and, 271
 - good governance and, 257
 - market/gift exchanges and, 260
- Dr Nakasone, 138
- Nakauchi, Hiro, 160
- Doctor Nantakam, 137, 140–141
- National Apex Committee for Stem
 - Cell Research and Therapy (NAC-SCRT)(India), 52, 80, 219, 235
- National Center for Child Health and
 - Development (Tokyo), 133
- National Centre for Human Stem Cell
 - Research Engineering (NC-SCRE), 76

- National Development and Reform Commission (China), 71, 76
- National Ethics Committees, 57
- National Guidelines for Stem Cell Research (2013) (India), 80–81, 219
- National Guidelines for Stem Cell Research (2017) (India), 234–235
- National Health and Family Planning Commission (NHFP), 67–68
- National Health Commission (NHC) (China), 237
- National Health Service (NHS) (UK), 51, 101, 238
- National Institute for Health and Care Excellence (NICE), 51
- National Institute for Health and Care Research (NIHR) (UK), 101
- National Institute of Advanced Industrial Science and Technology (NAIST), 133
- National Institute of Health (NIH) (Japan), 225
- National Institute of Health (NIH) (Korea), 232
- National Institute of Health (NIH) (USA), 53, 109
- Clinicaltrials.gov database, 115
- funding by, 223
- National Key Research and Development Program ‘Stem Cell and Transformation Research’ (China), 237
- National Medical Products Administration (NMPA) (China), 237
- National Organization for Rare Disorders (NORD), 254
- National Stem Cell Engineering (NSCE) Industrialization Base, 71
- nation-states, 38
- cost-benefit analysis and, 248
- globalisation and, 246–248
- immunity metaphors and, 92–93
- monopoly and, 3
- policy formation and, 45–47
- power and, 94
- regulatory boundary-work and, 28, 44–45
- regulatory gaps and, 206
- regulatory governance and, 5
- regulatory immune-tolerance and, 95
- Self and, 29
- social contract and, 257
- state support brokerage, 217, 219–221
- support for investment by, 249–250
- transcendental authority and, 260
- trust and, 205
- See also* regulatory governance
- Nature Cell, 234
- negotiation, 145
- collaboration and, 127–128
- levels of organisation and, 216
- regulatory brokerage and, 239
- regulatory capital and, 126
- neoliberalism, 4
- FTCM and, 181
- outsourcing regulation and, 215
- regulatory boundary-work and, 64
- regulatory capitalism and, 33–36
- Netherlands, 118, 183
- networks, 18
- alternative therapeutic practices and, 63
- biomedical platforms and, 82
- case-studies of, 19
- complexity of, 70
- entrepreneurism and, 82
- funding through, 72
- Guangzhou Alliance and, 74–75
- regulatory boundary-work and, 60–62
- regulatory orientation and, 77–78
- Zhao access to, 71. *See also* health organisations; organisational levels; patient organisations
- Neuralstem, 73
- Neurogen, 50, 235
- neurorestorative therapies, 61
- New Drugs and Clinical Trial Rules (India), 235
- Niscell, 56
- non-disclosure agreements (NDA), 223
- non-governmental organisations (NGOs), 188
- non-homologous use, 113
- non-political organisations (NPOs), 188
- non-routine use, 53

- Non-Self, 29
- Norio, Nakatsuji, 175
- normalcy, 204, 254
- North America, 114
- 'Notification on Self-Evaluation and Self-Correction Work regarding the Development of Clinical Stem Cell Research and Applications' (MoH 2011), 68, 298
- Novartis, 249
- Novumcella, 235
- objectification, 263–265
- Office of Medical Innovation (Japan), 221
- off-the-shelf therapies, 171
 - AJS and, 178
 - state investment and, 249
- Okano, Hideyuki, 160
- Okano, Teruo, 221–222
- oligopoly, 34
- oocyte sourcing, 11, 176
- opportunistic regulatory brokerage, 210–212, 216–217, 219, 224, 239
 - slow science and, 214
- organ bioengineering, 101
- Organisation for Economic Co-operation and Development (OECD), 4
- organisational level. *See also* health organisations; networks; patient organisations.
- organisational levels, 216
- orientations. *See* regulatory orientation
- Orphan Drug Designation (ODD), 50
- Osaka Declaration, 222
- Osiris, 74
- osteoarthritis, 58, 125, 133, 135, 142–143
- osteoporosis, 252
- Other-ability movement, 184
 - normalcy and, 204
- Othering, 264–265
- Others, 26, 92, 211
 - immunity metaphors and, 92
 - snake-oil and, 42
- pain management, 187, 192
- Pal, Ratan (pseudonym), 81–82
- parent organisations, 187
- Parents of Patients with Muscular Dystrophy Organization (PPMDO), 187
- Parkinson's Disease, 105, 169–170, 178
 - small-scale studies and, 107
- parliamentary discussion, 248
- Patel, Lord Kamlesh, 251
- Patent Act (Japan), 158
- patient choice, 107, 111
- patient confidentiality, 110
- patient engagement, 257–258
- patient financial contributions, 106
 - Australia and, 117
 - Beike and, 109, 111
 - ethnicity of, 107
 - US and, 114–115
- Patient For Stem Cells, 115
- patient movements, 30
 - Deane-Drummond and, 266
 - deregulation and, 154
 - experimentation and, 205–206
 - HOs and, 181–184, 186, 189, 193–195
 - knowledge activism and, 199–200
 - regulatory brokerage and, 207
- patient needs, 42
 - AJS and, 174, 178
 - AJS lack of priority for, 164
 - caring solidarity and, 214, 240
 - CGTs and, 227
 - disability and, 190–193
 - down-regulation and, 184
 - global sharing of, 204
 - local communities and, 268
 - misrecognition and, 31, 153, 228
 - political desirability of, 104
 - regulatory tolerance and, 121
 - regulatory violence and, 2, 185
- patient organisations: *See also* health organisations; networks; organisational levels
- patient rights, 202
- patients, access to, 260–263
- Pei Duanqing, 74
- Peking Union Medical College (PUMC), 71
 - collaboration with, 76
 - Institute of Hematology of, 71–72

- People's Liberation Army (PLA), 73
 307 Hospital patients at, 70
 performance, 20, 23, 25, 150–151, 154, 207
 All Japan System and, 30, 154
 international dynamics of, 209
 political movements and, 19, 31, 52
 regulation as, 7
 regulatory boundary-work and, 99
 regulatory brokerage and, 217
 regulatory change and, 18
 regulatory discrepancies and, 245
 regulatory flexibility and, 5
 regulatory redemption and, 151
 varying enactments of, 149
 permissive regulation, 113
 AJS and, 178–179
 Australia and, 116–117
 HOs and, 205
 Japan and, 224
 Japanese–Thai collaboration and, 144
 prohibitive regulation and, 239
 regulatory brokerage and, 210, 239
 Pfizer, 176
 Pharmaceutical Affairs Law (PAL), 58
 Pharmaceutical and Medical Drugs
 Agency (PMDA) (Japan), 133
 pharmaceuticals, 16–17, 101, 143, 205
 Chinese classification as, 68
 FTCM and, 181
 HOs and, 198
 industrial standards and, 176
 lowering costs and, 183
 monopoly of, 205
 rogue practices and, 197
 takeover targets and, 249
 Pharmaceuticals and Medical Devices
 Agency (PMDA)(Japan), 58, 159,
 169–170
 global brokerage and, 229–230
 GMP and, 173
 INDs and, 173
 internationalisation and, 177
 Japanese–Thai collaboration and,
 145
 Kanagawa Centre and, 226
 patient financial contributions in,
 106
 predatory firms and, 234
 product approvals and, 180
 Taiwan and, 236
 time-conditioned approvals and, 241
 Pharmaceuticals, Medical Devices, and
 Other Therapeutic Products Act
 (PMD Act), 58
 international brokerage and, 225
 JSRM and, 222
 Parkinson's Disease and, 170
 regulatory immunity and, 240
 state investment and, 252
 phase three trials, 181
 phase two trials, 181
 physical exercise, 195
 placebos, 55, 107, 110
 Plan for the Promotion of Medical
 Research and Development, 219
 platelet prduction, 173
 pluripotent stem cells (PSCs), 10
 classifications of, 175–176
 iPSCs and, 11–12
 ISCBI and, 174
 upscaling production and, 249
 Poland, 120
 Polanyi, Michael, 34
 policy formation, 45–47
 political desire, 121
 experimentation and, 105
 regulatory harmonisation
 and, 103
 politics, 23–25, 29, 151, 186–190
 AJS and, 156, 163, 174, 177–178
 effectiveness in, 258
 formation of political society and,
 257
 globalisation and, 246–248
 HOs and, 204
 identity and, 203, 206
 misrecognition and, 152–153
 regulatory boundary-work and, 52
 regulatory immunity and, 245
 regulatory redemption and,
 149–155
 social contract and, 258–259
 See also regulatory boundary-work
 polycentric regulation, 4
 pop-up markets, 107
 poverty, 203, 261

- power, 157
 - AJS and, 168
 - nation-states and, 94
 - regulatory redemption and, 129, 150
 - transcendental forms of, 70
 - transfer of, 247
- pragmatism, 203
 - trial design and, 262
- pre-market authorisation, 114
- prenatal genetic testing, 187
- primary care, 268
- primary prevention of medical conditions, 268
- Priority Medicine (PRIME), 119
- private interest theories, 6
- privatisation, 35
- product functionality, 85
- production, 53, 101
 - dialectic of, 150–151, 155, 163
 - global expansion of, 35
- profit, 107
 - caring solidarity and, 270
 - high-risk strategies and, 246
 - political desire and, 105
- prohibitive regulation, 113
 - active brokerage and, 221
 - FTCM and, 183
 - Japan–Thailand collaboration and, 128
 - opportunistic brokerage and, 239
 - regulatory brokerage and, 210, 217
 - regulatory immunity and, 240
- Promising Innovative Medicine (PIM) designation, 51
- protectionism, 34
- prudence, 27, 32, 214, 263
 - caring solidarity and, 212, 270
 - common good and, 265–266
 - local notions of wisdom and, 246
 - utilitarianism and, 269
 - wisdom and, 268
 - See also* caring solidarity
- Prudent Healthcare, 266
- public choice theory, 6
- public discussion, 22
- public interest theories, 6
 - regulatory reputation and, 91
- public needs, 45
- publication of research, 134
- pure vs. applied science, 159
- Quality Control Standards for Clinical Drug Trials' (CFDA), 67
- race, 262
- radical regulatory change, 42, 47, 58–60, 63
 - AJS and, 162
 - South Korea and, 64
- randomised control trials (RCTs), 53–55
 - adverse effects and, 106
 - ethical appraisal of, 107–108
 - kosher/rogue binary and, 103
 - poor insurance conditions and, 202
 - universal regulation and, 105–106
 - See also* clinical research trials (CRTs)
- rare disease criteria, 50
- rational individualism, 263
- RBio, 234
- reactive brokerage, 224, 231
 - forms of, 217
- reconstructive procedures, 84–85
- recruiter patients, 182
- Red Cross, 138
- red envelopes (bribes), 111
- redemption. *See* regulatory redemption
- reform. *See* regulatory reform
- regenerative medicine, 10–13, 165, 176–177
 - experimental therapy, 16–18
 - foreseeable harm and, 1–2
 - global dynamics of, 18–19
 - investment in, 13–14
 - See under* regulation
- Regenerative Medicine* (journal), 117
- Regenerative Medicine Expert Group (House of Lords, UK), 238
- Regenerative Medicine Industrialization Task Force (RMIT), 226
- Regenerative Medicine Law (Japan), 238
- Regenerative Medicine Markets Analysis and Forecast, 13
- Regenerative Medicine Promotion Act (RMP Act), 222, 241, 258
- Regenerative Sciences, 104

- Regenexx, 104, 115
- registries, 200–202
- REGROW-Act (USA), 232, 235, 241
- regulation, 3, 14
 - alternative forms of, 15
 - Black on, 215
 - change process and, 20
 - definitions of, 4
 - experimental practices and, 16–18
 - global dynamics of, 18–19
 - Japanese–Thai collaboration and, 140–143
 - multiple pressures on, 7
 - neoliberalism and, 4–5
 - rebellion against dominant modes of, 60
 - regulatee binary and, 7
 - regulatory violence and, 21
 - scientific rationale of, 28
 - theories of, 5–7
- Regulation on the Review and Authorization of Biological Products (South Korea, 57
- regulatory acceleration, 48
 - Australia and, 118
 - exemptions and, 205
 - fast-track approval and, 57
 - HOs and, 190
 - PMDA and, 180
 - R-CPX and, 142
 - regulatory brokerage and, 210
 - US and, 114–115
- regulatory adjustment, 46, 118, 231, 240
- regulatory agencies, 107
- regulatory assets, 136
- regulatory authority, 48
- regulatory boundary-making, 29
 - caring solidarity and, 270
 - international brokerage and, 228
 - Japanese style of, 219
 - performance and, 149
 - scapegoating and, 97
- regulatory boundary-work, 23, 25, 37–42, 62–64
 - authority and, 48–49
 - collaboration and, 124
 - ethical binaries and, 123
 - factors underpinning, 59
 - HICs and, 121
 - innovation and, 52
 - international networks and, 60–62
 - Japanese–Thai collaboration and, 144
 - LMICs and, 78, 88–89
 - local contexts for, 52
 - national conditions and, 45–47
 - nation-state politics and, 28
 - politics of reputation and, 91–92
 - RCTs and, 55
 - regulatory concepts and, 211
 - regulatory immunity and, 28, 99
 - regulatory orientation and, 89
 - regulatory reputation and, 102
 - scientific boundary-work and, 42–44
 - state governance and, 44–45
 - strategic practices of, 27
 - West and, 113
- regulatory brokerage, 3, 23, 25, 27
 - AJS and, 162, 180
 - down-regulation and, 254
 - five forms of, 216–217
 - foreseeable harm and, 215
 - global brokerage and, 228–231
 - harmful consequences of, 243
 - illegitimate aims of, 246
 - illegitimate reasons for, 244
 - informal forms of, 217–219
 - international form of, 224–228
 - justice and, 269
 - marginal standards and, 35
 - neoliberalism and, 33
 - organisational levels of, 216
 - prohibitive regulation and, 239
 - reform and, 221, 224
 - regulatory boundary-work and, 46
 - regulatory capacity building and, 28
 - regulatory capitalism and, 64
 - regulatory difference and, 245
 - regulatory discrepancies and, 239
 - regulatory immunity and, 89
 - regulatory redemption and, 150, 153
 - regulatory violence and, 31, 209–212, 242–243
 - research therapy tension and, 15
 - state support and, 219–221

- regulatory capacity building, 23, 25, 28, 30
 - China and, 67–69
 - competition and, 88
 - hegemony and, 89
 - India and, 80
 - Japanese–Thai collaboration and, 144
 - LMICs and, 66
 - prohibitive regulation and, 240
 - regulatory concepts and, 211
 - regulatory orientation and, 77–78
 - Stempeutics and, 83–84, 87
 - See also* regulatory orientations
- regulatory capital, 29
 - active brokerage and, 221
 - centrality of, 29
 - collaboration and, 125–126
 - commodification and, 239
 - international brokerage and, 225, 228
 - Japanese reform and, 224
 - Japanese–Thai collaboration and, 127–128, 133, 143–147
 - regulatory brokerage and, 209
 - regulatory concepts and, 211
 - regulatory difference and, 245
 - regulatory immunity and, 240
 - state support brokerage and, 219–221
- regulatory capitalism, 2, 4–6, 15, 25–27
 - Beike and, 111
 - caring solidarity and, 31, 270–271
 - collateral sacrifice and, 248
 - commodification and, 263
 - competitive advantages under, 123
 - competitive strategies and, 246
 - conceptual terminology of, 23
 - creative desire and, 263
 - global brokerage and, 231
 - global dynamics of, 18–19, 204
 - globalisation and, 247
 - immunity metaphors and, 92
 - Japanese–Thai collaboration and, 147
 - large LMICs and, 108
 - LMICs and, 88
 - local communities and, 243
 - mutuality and, 257
 - neoliberalism and, 33–36
 - patient movements and, 30
 - patient populations and, 260, 262–263
 - political movements and, 154
 - regulatory boundary-work and, 39–40, 64
 - regulatory brokerage and, 213
 - regulatory immune-vacuum and, 93, 96–97
 - regulatory immunity and, 94
 - regulatory redemption and, 150
 - regulatory reputation and, 37–38
 - regulatory theories and, 216
 - social contract and, 243, 246, 256, 259–260
 - stem cell trials and, 13
 - theory of, 5
 - Regulatory Capitalism* (Braithwaite), 35
 - regulatory capture theory, 6, 40, 215
 - regulatory cascades, 208, 212, 215–216, 231
- regulatory competition, 2, 27
 - China and, 237
 - global dynamics of, 18
 - increase in collaboration and, 42
 - mimetic desire and, 31
- regulatory compromise, 3
- regulatory consciousness, 245
- regulatory contagion, 147
- regulatory convenience, 79
- regulatory development, 85, 87
 - global dynamics of, 28, 89
 - LMICs and, 88
- regulatory difference, 211, 266
 - Japan and, 234
 - local dilemmas and, 66
 - regulatory brokerage and, 245
 - regulatory capital and, 245
 - Stempeutics and, 87
- regulatory discrepancies, 31, 40, 97, 152, 239, 242
 - agency and, 208
 - AJS and, 155
 - collaboration and, 216
 - competitive desire and, 213
 - Japanese–Thai collaboration and, 125–127, 130, 143, 145–146
 - parallel studies and, 228
 - performance and, 245

- reactive brokerage and, 224
- regulatory brokerage and, 217–218
- regulatory capital and, 209
- regulatory immunity and, 125
- regulatory diversity, 63
- regulatory facilitation, 153
 - affordability and, 253
 - misrecognition and, 153
- regulatory flexibility, 145
 - COVID-19 and, 214
 - performance of, 5
- Regulatory Framework for Biologics, 116–117
- regulatory governance, 5–7
 - frictions in, 26
- regulatory harmonisation, 91, 113, 174
 - Asian regulation and, 144
 - global brokerage and, 228, 230
 - Japan–UK and, 227
 - political desirables in, 103
 - Stempeutics and, 87
 - WHO and, 100
 - WTO and, 123
- regulatory hegemony, 28
- regulatory ideals, 101, 121
 - political desirability and, 104
 - RCTs and, 105, 107
- regulatory immune tolerance, 28, 91, 93–96
 - regulatory concepts and, 211
 - scapegoating and, 96–97
 - See also* regulatory immunity; regulatory tolerance
- regulatory immune-vacuum, 93, 96–98
- regulatory immunity, 24–25, 28
 - AJS and, 179
 - Beike and, 111–112
 - collaboration and, 126, 239
 - competitive desire and, 240
 - establishment of law and, 93–94
 - global brokerage and, 231
 - Japan and, 151, 155, 219
 - Japanese–Thai collaboration and, 147
 - politicisation and, 245
 - regulatory boundary-work and, 99
 - regulatory brokerage and, 197
 - regulatory concepts and, 211
 - regulatory discrepancies and, 125
 - regulatory immune-tolerance and, 91, 94–96
 - regulatory immune-vacuum and, 96–98
 - regulatory redemption and, 150
 - regulatory reputation and, 91–93
 - Self and, 101, 103
 - South Korea and, 233
 - time-conditionally-approved products and, 224
 - trust and, 234
 - universal regulation and, 106
 - US and, 114
 - weakness of, 240
- regulatory immunisation, 113, 120–122
 - down-regulation and, 205
 - HOs and, 206
- regulatory impasse, 47, 63, 112
- regulatory inflation, 66
- regulatory infrastructures, 261
- regulatory knowledge, 245
- regulatory loopholes, 114
- regulatory manipulation, 21, 35
- regulatory objectivity, 43
- regulatory orientation, 69–70, 211
 - China and, 71, 75–78
 - India and, 88–89
 - Stempeutics and, 78–79, 81, 85
 - See also* regulatory capacity building
- regulatory pathways, 87
- regulatory patterns, 244
- regulatory permission, 48
- regulatory politics, 62
- regulatory redemption, 23, 25, 30, 149–151, 153–154
 - All Japan System and, 155–156, 159–160, 162–163
 - deregulation and, 184
 - down-regulation and, 181, 184, 205
 - FTCM and, 186
 - Japan's 2013 reforms and, 30
 - misrecognition and, 153, 177
 - overhyped celebration of, 245
 - patient movements and, 30, 182
 - reform and, 224
 - regulatory concepts and, 211
 - Taiwan and, 236
 - transcendental force and, 151–152

- regulatory reform, 127, 210, 231, 239
 - AJS and, 160, 163, 166, 168–169
 - cascades of, 216
 - China 2009 regulations and, 67
 - Comprehensive Special Zones and, 225
 - India and, 86
 - ISSCR and, 229
 - Japan and, 221–224, 234
 - Japanese–Thai collaboration and, 147
 - overhyping iPS and, 179
 - performance of, 154
 - regulatory capital and, 146
 - regulatory redemption and, 155–156, 159
 - scientific reality of, 177
 - South Korea and, 233
 - Taiwan and, 236
 - US influence on, 231–232
- regulatory reproduction, dialectic of, 151
- regulatory reputation, 28, 91
 - Australia and, 117
 - constrictive regulation and, 149
 - discursive messaging and, 96
 - EU and, 118
 - ICMS and, 61
 - India and, 78, 87
 - investment and, 57
 - Japan and, 155, 224
 - Japanese reforms and, 154
 - Japanese–Thai collaboration and, 128, 132, 134
 - manipulation of, 210–214
 - national income and, 99
 - public interest and, 81
 - R-CPX and, 143
 - regulatory immunity and, 91–93
 - regulatory redemption and, 150
 - risks to, 101–103, 170
 - soft law and, 221
 - Stempeutics and, 85
- regulatory resistance, 79
- regulatory ritualisation, 24–25
 - misrecognition and, 153–154
 - R-CPX and, 147
 - regulatory redemption and, 152
- Regulatory Science Centre, 230
- regulatory sovereignty, 246
- regulatory space, 48
- regulatory state approach (Levi-Faur), 5
- regulatory tolerance, 28–29
 - Australia and, 116–117
 - Beike and, 108, 112
 - EU and, 120
 - HICs and, 112, 121
 - India and, 235
 - international brokerage and, 228
 - Japan–India collaboration and, 219
 - regulatory capital and, 147
 - regulatory immune-tolerance and, 94–96
 - regulatory redemption and, 150
 - risk differentiation and, 106
 - Self and, 101, 103
 - Therapeutic Goods regulation and, 122
 - universal regulation and, 99, 106
 - US and, 114–115, 240
- regulatory uncertainty, 18
 - medical device regulation and, 62
- regulatory violation, 8
- regulatory violence, 2–4, 24, 26–27
 - caring solidarity and, 269–270
 - competitive desire and, 31
 - creative desire and, 263–264
 - definitions of violence and, 7–9
 - down-regulation and, 30
 - foreseeable harm and, 1–2
 - global dynamics of, 20
 - globalisation and, 246–248
 - immunity metaphors and, 92
 - local communities and, 266–268
 - patients movements and, 31
 - politics vs. capitalism and, 216
 - regulatory brokerage and, 31, 209–213, 242–243, 245–246
 - regulatory immunity and, 93
 - regulatory redemption and, 30
 - research therapy tension and, 15
 - sacrifice of patient interests and, 248
 - sustainability of healthcare and, 21
- rehabilitation, 195
- reimbursement eligibility, 225

- Reliable and Effective Growth for
Regenerative Health Options that
Improve Wellness Act
(REGROW), 254
- Reliance, 56
- REMEDI, 119
- Remudy (MD-research collective), 195
- Reproductive & Genetic Hospital
CITIC-Xiangya, 75–76
- reputation. *See* regulatory reputation
- Research Institute of Economy, Trade
and Industry (RIETI), 233
- resistance, 44
- responsible innovation, 78–79, 81, 86
- responsive regulation, 215
- retinal pigment epithelium (RPE), 165,
167, 170–171
- ‘return to society’ aims, 187
- Revised Pharmaceutical Affairs Law, 158
- right to try laws, 15, 154
- RIKEN Centre for Developmental
Biology (CDB), 160, 163, 166
closure of, 177
- rising powers, 42, 88–89
- risk-benefits analysis, 268–269
- risk-management, 224, 247–248
differentiation of, 106
high-profit margins and, 246
industrial standards and, 176
- RNL Bio, 234
- RNL/Celltex, 53
- Roadmap for Regenerative Medicine,
141
- Robot Cultivate Cell Culture (R-CPX),
125–126, 128–130, 144–145
Japanese–Thai collaboration and,
132, 145
medical benefits of, 136–137
proving worth of, 144
regulation and, 140–143
regulatory capital and, 143, 146–147
scientific results of, 133–136
trust in collaboration and, 137–139
- Robotic Stem Cell Incubation
Laboratory, 137
- rogue practices, 24–25, 29, 41, 63
Beike and, 111
discursive identification and, 97
grey areas and, 95
industry collaboration and, 197
RCTs and, 103
regulatory immunity and, 93
regulatory reputation and, 102
US and, 114–115
X-Cell and, 118
- Roman law, 95
- rule by nobody, 9
- Russia, 42
- sacrificeable victims, 259–260
- same surgical procedure exception, 114
- Sasai, Yoshiki, 160
- Sawa, Yoshiki, 133, 135, 142, 222
- scaffolding, 135, 175
- Scandinavia, 183
- scapegoating, 29, 93, 96–97, 264
caring solidarity and, 270
cultures of, 102
EU and, 120
HICs and, 121
Thailand and, 125
- SCI USA, 61
- science and technology studies (STS)
approaches, 66, 78
biomedical platform debates and, 89
- scientific atheism, 102
- scientific boundary-work, 37, 42–44
- scientific culture, 52
- scientific rationales, 89
- scientific results, 133–136
differing priorities within, 143
- scientific uncertainty, 104
stimulus to research of, 105
- SCI-Net, 67
- secrecy, 172, 178
- Seer, 75
- Self and Non-Self, 29, 92
immunity metaphors and, 92–93
mimetic rivalry and, 93, 100
misrecognition and, 228
regulatory tolerance and, 101, 103
rogue competitors and, 97
- self-assessment, 61
- self-help, 74
- self-regulation, 94, 100, 103
- semi-private enterprises, 75–76

- Sendai virus, 172
 Sent, E. M., 159
 Sharma, Alok, 235
 Shenzhen (China), 109
 Shirai (immunologist), 174
 Shirakawa, 164
 Siebers, Tobin, 184
 Simons, Henry, 34
 Singapore, 57
 Japanese–Thai collaboration and, 138
 Singh, Sanjay, 81–82, 85
 SiriCell, 57
 Sirindhorn, Crown Princess Maha
 Chakri, 138
 small-scale studies, 107
 Smith, Adam, 34
 snake-oil science and treatments, 24
 Beike and, 111
 EU and, 120
 HICs and, 42
 regulatory violence and, 8
 Thailand and, 125
 Traditional Chinese Medicine and, 102
 social care, 268
 social knowledge, 262
 social-contract, 246, 256–260, 271
 investments too large to fail and, 256
 Lancet Report and, 243
 patient populations and, 262–263
 sacrificeable victims, 259–260
 socio-economic environment, 261–262
 socio-political positions, 152
 socio-scientific network structures, 83
 soft law, 48
 innovation and, 52
 regulatory reputation and, 221
 somatic cell nuclear transfer (SCNT), 11
 somatic stem cell therapy, 10–12
 dual-track system and, 237
 EU and, 118
 promise of, 143
 Dr Sombat, 134, 137–140, 142
 South Korea, 232–233
 Australia and, 117
 fast-track pathways and, 57–60
 HOs and, 196, 205
 India and, 235
 industry collaboration and, 198
 influence of reform and, 231–232
 Japan and, 233
 Japanese–Thai collaboration and, 138
 knowledge activism and, 201–202
 LMIC collaboration and, 57
 market acceleration and, 51
 regulatory boundary-work and, 64
 regulatory dynamics of, 63
 regulatory immunity and, 240
 SCI and, 194–195
 shared scientific cultures and, 53
 stem cell trials in, 13
 Specials scheme (UK), 50
 Spinal Cord Injury (SCI), 30, 105, 185–186
 diverse needs of disabled and, 190–192
 HICs and, 196
 HOs and, 182
 identity politics and, 204
 industry collaboration and, 197–198
 knowledge activism and, 200–203
 locally situated demands and, 192–195
 patient movements and, 183
 personal decision-making and, 255
 political governance and, 186–188, 190
 problems of global activism and, 203
 self-empowerment and, 189
 Spinal Cord Injury Network (SCIN),
 188, 194
 spotted regulatory brokerage, 26
 Sri Lanka, 188
 Srinivasan, Professor (pseudonym), 86
 stakeholders, 69, 150
 Stamina Foundation, 119–121
 standards, 43
 deviant forms of, 52
 See also regulatory boundary-work
Standards (Busch), 34
 STAP-cells (Stimulus-triggered
 acquisition of pluripotency), 177
 Stem Cell and Cell Based Products
 (SCCPs) designation, 80
 Stem Cell and Regenerative Medicine
 Strategy Working Group, 160
 Stem Cell Network (Canada), 60
 Stem cell Network Asia Pacific (SNAP),
 60
 Stem Cell Research Society of Thailand,
 140

- stem cell science, 10–12
 - debating distinctions among, 103
 - limited expert knowledge in, 86
 - See also* clinical research trials (CRTs); *under*regulation
- stem cell tourism, 102
 - Beike and, 109
 - HOs and, 195
 - patient movements and, 182
 - R-CPX and, 136
- Stemgenex, 115
- Stempeucare, 83–85
- Stempeucel, 83–84
 - 2013 regulation and, 235
- Stempeutics, 56, 59, 66, 81–83, 85–87
 - 2013 regulation and, 235
 - allogeneic stem cells and, 81–83
 - formulating regulation and, 88
 - responsible innovation and, 78–79
 - three-fold plan by, 83–85
 - unauthorised clinics and, 81
- Stempeutron, 83–85
- Stengers, Isabelle, 214
- strict regulation, 205
- structural factors, 247, 269
- structural violence, 8–9, 242
- subsidiarity principle, 118
- Sumitomo Dainippon Pharma Co, 170–171
- Sun Yat-Sen University, 77
- Sūpā Tokku (special disciplinary areas or networks), 158
- sustainable health, 2, 32, 246, 263
 - caring solidarity and, 270
 - Japan and, 267
- symbolism, 149
 - All Japan System and, 154, 168
 - R-CPX, 147
 - regulatory redemption and, 150–152
 - saving lives and, 153
- Taiwan, 53, 236–237
- Taiwan Association for Cellular Therapy, 236
- Taiwan Department of Public Health, 236
- Taiwan Food and Drugs Administration (Taiwan FDA), 236
- Takahashi, Jun, 169–170
- Takahashi, Kazutoshi, 11, 156–157
- Takahashi, Masayo, 163, 166–168, 170–171
 - Healios and, 177
- Takayama, Kazuo, 163
- Tanabe, Koji, 169–170
- Tanida (tissue engineer), 175
- TEDA development zone, 71
- Temcell, 225
- Temple, Sally, 235
- Terumo, 222, 225
- Texas (US), 53
- THAI [pseudonym], 125, 128, 131
 - R-CPX and, 136, 145
 - regulation and, 141
 - regulatory capital and, 147
 - regulatory reputation and, 134
 - trust and, 139
- Thai Food and Drug Administration (TFDA), 131, 138, 142–143, 145
- Thai Physician Association (TPA), 140
- Thai Revised Drug Act, 144
- Thailand, 131, 138, 142–143, 145
 - 2009 regulation and, 130
 - caring solidarity and, 241
 - collaboration with, 124–127
 - investment by, 56–57
 - patient populations and, 262
 - regulatory boundary-work and, 64
 - regulatory immunity and, 240
 - shared scientific cultures and, 53
 - state support brokerage and, 219–221
- thalassemia, 124, 136–137
- The Automation Partnership Biosystems (TAP Biosystems), 129
- therapeutic goods, 116–117, 121
- Therapeutic Goods Association (TGA), 117
- therapy provision, 80–83, 85–86, 88
 - Beike and, 110
 - R-CPX and, 136–137
 - regulatory immunisation and, 121
 - risk and, 135
 - symbolic value of saving lives in, 139
 - tension between clinical research trials and, 14–15

- TheraVita, 57
- Thomson, James, 11, 157
- 351 products, 114
- 361 products, 113
- Tianjin Amcell Gene Engineering Co., Ltd., 72
- Tianjin Huayuan Hi-tech Park, 71
- Tianjin Municipality, 70–72
- Tianjin Umbilical Cord Blood Bank, 71
- Tianjin Xiehe hospital, 72
- tiered payment systems, 198. *See also* healthcare insurance
- tiered risk system, 224
- TiGenix, 50
- time-conditioned approval, 224, 229
RMP and, 241
Taiwan and, 236
- tissue engineering, 175
- tissue regeneration, 84
- tissue-engineering centers (TECs), 74
- Toda, Yuzo, 230
- Tokyo University, 160
- tolerance. *See* regulatory tolerance
- Too Much Medicine, 266
- Tooke, Sir John, 251
- top-down approaches, 215
- Trade Related Aspects of Intellectual Property Rights (TRIPS), 36
- Traditional Chinese Medicine (TCM), 102, 192
- transcendental authority, 96, 151–152
caring solidarity and, 269
social contract and, 260
- translational research, 17, 39–40, 55
acceleration of, 51
AJS and, 179
bodily violence and, 247
competitive desire and, 251
credible authority and, 97
FDA and, 49
House of Lords and, 251
India and, 78, 82, 88
LMICs and, 56
medium-sized countries and, 57
regulatory brokerage and, 210
regulatory redemption and, 153
social contract and, 256
state investment and, 252
- transparency, 72
- trial design, 51
AJS and, 173–174
deficiencies in, 179
local conditions and, 262
- triangular mimetic desire, 26–27, 31
- trust, 137–139
HOs and, 194–195, 197–198
individual-rights discourses and, 203
Japan and, 234
Japanese–Thai collaboration and, 143
state regulators and, 205–206
- Tsai, T.-H., 236
- tumorigenicity, 12
- 21st Century Cures Act, 232
- 2001 moratorium on federal funding for human embryonic stem cell (hESC), 41
- UK–JAPAN Life Innovation Symposium, 226–228
- umbilical cord blood banks (UCB), 71–72, 76
Beike and, 110
- umbilical cord mesenchymal stem cells (US-MSCs), 108–109
- unauthorised practices, 16
Beike and, 111
closing clinics and, 103
formulating regulation and, 88
HOs and, 205
R-CPX and, 140
regulatory tolerance and, 107, 240
Stempeutics and, 87
US and, 114–115
- unclear/developing regulation, 47
- unethical practices, 22
collaboration on, 147
universal application and, 106
- Union Stem Cell & Gene Engineering (USCGEN), 71–72
- United Kingdom (UK), 197, 226–228
competition and, 101
Early Access to Medicine Scheme in, 51
HO resource competition in, 188
House of Lords debate in, 251–252
industry collaboration and, 198

- Japan and, 238
- Japanese investment and, 223
- needs of disabled and, 191
- SCI and, 193, 200
- soft law and, 48
- 'Specials scheme' in, 50
- United Kingdom Nuffield Council on Bioethics, 17
- United Kingdom Research and Innovation (UKRI), 112
- United Nations (UN), 267
- US Congress, 51
- US Court of Appeals, 114
- US Federal Trade Commission (FTC), 122
- US Food and Drug Administration (FDA), 113–115
 - accelerated approval and, 51
 - Biologics and, 116
 - compassionate treatment and, 50
 - conditional approval and, 254
 - direct-to-consumer and, 122
 - expanded access and, 115
 - forms of authority used by, 49
 - FTCM and, 181, 232
 - ICMS and, 61
 - IND programme and, 49
 - Japan and, 151
 - knowledge activism and, 200
 - minimal manipulation and, 53
 - Orphan Drug Designation and, 50
 - patient financial contributions in, 106
 - RCTs and, 55
 - Regenexx-C and, 104
 - right to try laws and, 15
 - same surgical procedure exception and, 114
 - scarcity of resources and, 39
 - unproven stem cell therapies and, 236
 - WHO and, 123
- United States of America (US), 113–115, 121–123
 - allogeneic stem cells and, 81
 - Australia and, 116–117
 - competition with Japan and, 233
 - conditional approval and, 254
 - ethical funding halt in, 101
 - EU and, 120
 - FTCM and, 181
 - HOs and, 205
 - India and, 80, 235–236
 - INDs and, 223
 - industry collaboration and, 197
 - influence of reform in, 231–232
 - international patient movements and, 154
 - knowledge activism and, 200, 202
 - market acceleration and, 51–52
 - minimal manipulation and, 53
 - modernity and, 113
 - off-label use in, 49
 - opposition to cooperation with, 177
 - patient financial contributions in, 106
 - patient movements and, 183–184
 - piecemeal regulation and, 59
 - platelet donations in, 173
 - private interest theories in, 6
 - pure science and, 159
 - RCTs and, 53–55
 - REGROW Bill and, 241
 - regulatory boundary-work and, 42
 - regulatory dynamics of, 63
 - regulatory overhaul and, 42
 - SCI and, 194–195
 - soft law and, 48
 - standards set by, 67
 - state funding and, 223
 - state investment and, 251
 - Stempeutics and, 86
 - UK–Japan collaboration and, 227
 - unauthorised stem cell-provision and, 240
 - Yamanaka and, 168
- universal prohibition, 111
- universal regulation, 102–103, 105–107
 - China and, 122
 - pluripotency and, 175
- University for Pregnant Women, 71
- University of Texas MD Cancer Anderson Centre, 56
- University of Wisconsin, Madison, 157
- university-linked alliances, 74
- unproven stem cell therapies, 235
- unrealistic hopes, 259

- upscaling production, 130
 - cost-benefits of, 256
 - Japan and, 229
 - R-CPX and, 137
 - state support brokerage and, 221
- US Stem Cell, 115
- US Stemology, 114
- utilitarian approaches, 269
- Valley of Death, the, 17
- venture capital, 223–224, 249
 - developmental pathway length and, 227
- victims, 264
 - sacrificeability of, 259–260
- Vietnam, 56–57, 64
- Dr Vimal(pseudonym), 86
- violence, 7–8
 - alternative methods and, 63
 - caring solidarity and, 270
 - cycles of revenge and, 259
 - definitions of, 7–9
 - establishment of law and, 93–94
 - exteriorisation of, 96
 - psychological forms of, 8
 - regulation and, 21
 - social contract and, 256
 - See also* regulatory violence
- virtue ethics, 266, 268–269
- Waseda University, 218
- wealth, 62
 - community and, 264
 - political identity and, 204
 - See also* high-income countries (HICs)
- Weber, Max, 3
- WeChat (weixin), 194
- well regulated countries, 113
- Wen Jiabao, 110
- Western society, 15, 41, 112–113
 - down-regulation and, 184
 - HOs and, 186, 193, 205
 - knowledge activism and, 199
 - patient movements and, 182
 - political influence of, 188
 - SCI and, 186, 194
 - Western-hegemony theory and, 38, 40
- Wharton's jelly cells, 120
- wheelchair access, 191, 195, 197
- whole-genome sequencing, 170
- Dr Wilipana, 135, 138–141, 221
- Willis, George Philip, Lord of
 - Knaresborough, 251
- Windholz, Eric, 5–6
- wisdom, 268, 270
 - local notions of, 246, 263
 - prudence as, 266
- Wise Young, 61
- women, expectation to care and, 192
- workspaces, 188–190
 - cultural politics and, 196
 - health activism and, 204
- World Health Organization (WHO),
 - 100, 122–123
 - universal health coverage and, 267
- World Medical Association Declaration
 - of Helsinki on Ethical Principles
 - for Medical Research Involving
 - Human Subjects (WMA 2018), 50
- World Premier International Research
 - Centre Initiative (WPI), 164
- World Trade Organization (WTO), 36, 123
- Wu Medical Centre, 57
- Wu Zuke, 76
- X-Cell, 118
- Xi Jinping, 112
- Xiang Hu, 112
- Xiangya Reproductive Hospital, 75
- Yamanaka assays, 169
- Yamanaka methods, 178–179
- Yamanaka, Shinya, 11, 134, 156–157
 - AJS and, 160
 - doubt spread by, 175
 - Nobel Prize for, 136
 - product standardisation and, 174
 - Sendai virus and, 172
 - state investment and, 250
 - Yamanaka assay and, 167–169
- Yao-Chan Chen, 236
- Yokohama Declaration, 222–223
- Z Centre for Regenerative Medicine
 - (ZCRM), 218–219
- Zhao Chunhua, 70–71, 76
- Zhejiang University, 70
- Zhongyuan Union Stem Cell
 - Bioengineering Corporation, 56, 112